Cutaneous T-cell lymphoma - mogamulizumab or vorinostat - initial authority application form (PB216)

Use this form to apply for initial PBS-subsidised treatment with mogamulizumab or vorinostat for cutaneous T-cell lymphoma.

Page last updated: 2 April 2026.
QC 37761